Gland Pharma receives approval for Latanoprost Opthalmic Solution, 0.005%
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
The collaboration offers opportunities for training, research fellowships, workshops and conferences at palliative care centers managed by Ajit Isaac Foundation
Subscribe To Our Newsletter & Stay Updated